By mapping cellular composition and transcriptional programs across spatial compartments, this work demonstrates the unique value of spatial transcriptomics in uncovering clinically relevant heterogeneity in SCLC—offering mechanistic insights into subtype-specific immune interactions and identifying REST as a potential biomarker for therapeutic stratification (Figure 4). This evidence concerns the gene REST and small cell lung carcinoma.